RBC names Gilead a top biotech pick based on valuation

A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.

David Paul Morris | Bloomberg | Getty Images

Now is a good entry point into Gilead’s stock as the company begins to stabilize, while still trading at a discount to its peers, according to RBC Capital Markets.

The firm named biotechnology company Gilead to its top picks list and maintained its $91 price target, a near 34% upside.

Articles You May Like

EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
UnitedHealth’s first-quarter report will offer a window into Change cyberattack costs
Top Wall Street analysts like these 3 stocks for their growth prospects
Wells Fargo shares fall as lower interest income cuts into profits
Boeing defends 787 Dreamliner safety after whistleblower alleged structural flaws

Leave a Reply

Your email address will not be published. Required fields are marked *